Pre-Open Movers 11/09: (OTIC) (SAGE) (ROKU) Higher; (VSTO) (OPK) (EPC) Lower (more...)

November 9, 2017 9:23 AM EST

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Today's Pre-Open Movers

Otonomy, Inc. (NASDAQ: OTIC) 108.8% HIGHER; announced that the AVERTS-2 Phase 3 clinical trial of OTIVIDEX in patients with Meniere's disease achieved its primary efficacy endpoint (p value = 0.029). Otonomy plans to review these results with the U.S. Food and Drug Administration (FDA) and discuss clinical requirements for registration of OTIVIDEX for patients with Meniere's disease.

Sage Therapeutics (NASDAQ: SAGE) 43.8% HIGHER; announced positive top-line results from two Phase 3 clinical trials with its proprietary i.v. formulation of brexanolone (USAN; formerly SAGE-547); Study 202B in severe postpartum depression (PPD) and Study 202C in moderate PPD. Brexanolone achieved the primary endpoint in both trials, a mean reduction from baseline in the Hamilton Rating Scale for Depression (HAM-D) total score compared to placebo at 60 hours (Study 202B: p=0.0242 for 90 µg/kg/h dose and p=0.0011 for 60 µg/kg/h dose; Study 202C: p=0.0160 for 90 µg/kg/h dose). Patients treated with brexanolone demonstrated mean reductions from baseline in HAM-D total scores of 14 to 20 points at 60 hours maintained to 30 days in both trials. Brexanolone was generally well tolerated and showed a similar safety profile as seen in earlier studies.

Roku (NASDAQ: ROKU) 29.3% HIGHER; reported Q3 EPS of ($0.10), $1.30 better than the analyst estimate of ($1.40). Revenue for the quarter came in at $124.8 million versus the consensus estimate of $110.47 million.

Vista Outdoor (NYSE: VSTO) 26.8% LOWER; reported Q2 EPS of $0.34, $0.07 better than the analyst estimate of $0.27. Revenue for the quarter came in at $587 million versus the consensus estimate of $589.98 million. Vista Outdoor sees FY2018 EPS of $0.50-$0.60, versus the consensus of $1.24. Vista Outdoor sees FY2018 revenue of $2.24-2.26 million, versus the consensus of $2.39 million.

Bristow Group (NYSE: BRS) 22.3% HIGHER; reported Q2 EPS of ($0.33), versus ($0.35) reported last year. Revenue for the quarter came in at $357.99 million versus the consensus estimate of $343.97 million.

Maiden Holdings (NASDAQ: MHLD) 20.8% LOWER; reported Q3 EPS of $0.74, versus $0.40 reported last year.

Marinus Pharmaceuticals (NASDAQ: MRNS) 20.3% HIGHER; gains in sympathy with SAGE.

Overstock.com (NASDAQ: OSTK) 14.8% HIGHER; reported Q3 EPS of ($0.03), versus ($0.12) reported last year. Revenues fell 4% to $424 million. The company sold a warrant to a fund affiliated with Passport Capital LLC for $2.6 million to purchase 1,250,000 shares of our common stock at $40.45 per share until February 7, 2018. They also sold a warrant to Quantum Partners LP for $4 million to purchase 2,472,188 shares of our common stock at $40.45 per share until January 2, 2018. Quantum Partners LP is a private investment fund managed by Soros Fund Management LLC.

MeetMe (NASDAQ: MEET) 14.5% LOWER; reported Q3 EPS of $0.11, $0.01 better than the analyst estimate of $0.10. Revenue for the quarter came in at $32.2 million versus the consensus estimate of $32.34 million. GUIDANCE: MeetMe sees Q4 2017 revenue of $36.5-38 million. MeetMe sees FY 2017 revenue of $120.1-121.6 million.

OPKO Health (NASDAQ: OPK) 14% LOWER; reported Q3 EPS of ($0.08), $0.03 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $263.5 million versus the consensus estimate of $319.43 million.

Coty (NYSE: COTY) 13.8% HIGHER; reported Q1 EPS of $0.10, $0.03 better than the analyst estimate of $0.07. Revenue for the quarter came in at $2.24 billion versus the consensus estimate of $2.24 billion.

SolarEdge Technologies (NASDAQ: SEDG) 13.4% HIGHER; reported Q3 EPS of $0.66, $0.11 better than the analyst estimate of $0.55. Revenue for the quarter came in at $166.6 million versus the consensus estimate of $159.18 million.

Party City (NYSE: PRTY) 12.2% HIGHER; reported Q3 EPS of $0.13, in-line with the analyst estimate of $0.13. Revenue for the quarter came in at $560.1 million versus the consensus estimate of $587.77 million. Share Repurchase Program: The Company also announced today that its Board of Directors has approved a share repurchase program under which the Company may purchase up to $100 million of its outstanding common shares from time to time, depending upon a variety of factors, including market and industry conditions, share price, regulatory requirements and other corporate considerations, as determined by the Company from time to time.

Edgewell Personal Care Company (NYSE: EPC) 11.9% LOWER; reported Q4 EPS of $1.00, $0.03 worse than the analyst estimate of $1.03. Revenue for the quarter came in at $564.9 million versus the consensus estimate of $588.28 million. Edgewell Personal Care Company sees FY2018 EPS of $3.80-$4.00, versus the consensus of $4.13.

Perrigo (NYSE: PRGO) 11.2% HIGHER; reported Q3 Adj. EPS of $1.39, $0.28 better than the analyst estimate of $1.11. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. GUIDANCE: Perrigo sees Q4 2017 EPS of $4.80-$4.95, versus the consensus of $4.59.

CenturyLink (NYSE: CTL) 9.3% LOWER; reported Q3 EPS of $0.42, $0.03 worse than the analyst estimate of $0.45. Revenue for the quarter came in at $4 billion versus the consensus estimate of $4.06 billion.

Stericycle (NASDAQ: SRCL) 8.7% LOWER; reported Q3 EPS of $1.10, $0.04 worse than the analyst estimate of $1.14. Revenue for the quarter came in at $882.5 million versus the consensus estimate of $895.99 million.

Collegium Pharma (NASDAQ: COLL) 7.9% HIGHER; reported Q3 EPS of ($0.45), $0.29 better than the analyst estimate of ($0.74).

Pegasystems (NASDAQ: PEGA) 7.4% LOWER; reported Q3 EPS of $0.05, $0.12 worse than the analyst estimate of $0.17. Revenue for the quarter came in at $179.82 million versus the consensus estimate of $200.15 million.

Kohl's Corp. (NYSE: KSS) 7.3% LOWER; reported Q3 EPS of $0.70, $0.02 worse than the analyst estimate of $0.72. Revenue for the quarter came in at $4.3 billion versus the consensus estimate of $4.3 billion. Comps increased 0.1%. ​Company sees FY EPS of $3.60 to $3.80 consensus of $3.76.

James River Group Holdings, Ltd. (NASDAQ: JRVR) 6.5% LOWER; announced today that certain of the Companys shareholders intend to offer in an underwritten public offering an aggregate of 3,000,000 of the Companys common shares (the Selling Shareholders). The Selling Shareholders will receive all of the net proceeds from this offering. The underwriters have a 30-day option to purchase up to an additional 450,000 common shares from certain of the Selling Shareholders. No shares are being sold by the Company.

Hologic (NASDAQ: HOLX) 6.4% LOWER; reported Q4 EPS of $0.50, $0.01 better than the analyst estimate of $0.49. Revenue for the quarter came in at $802.9 million versus the consensus estimate of $792.54 million.

Canadian Solar (NASDAQ: CSIQ) 4.6% LOWER; reported Q3 EPS of $0.22, $0.04 worse than the analyst estimate of $0.26. Revenue for the quarter came in at $912.2 million versus the consensus estimate of $813.36 million.

Monster Beverage (NASDAQ: MNST) 3.4% LOWER; reported Q3 EPS of $0.38, $0.02 worse than the analyst estimate of $0.40. Revenue for the quarter came in at $909.5 million versus the consensus estimate of $903.64 million.

Twilio (NYSE: TWLO) 3.3% HIGHER; reported Q3 EPS of ($0.08), in-line with the analyst estimate of ($0.08). Revenue for the quarter came in at $100.5 million versus the consensus estimate of $92.55 million. GUIDANCE: Twilio sees Q4 2017 EPS of ($0.06)-($0.05). Twilio sees Q4 2017 revenue of $102.5-104.5 million. Twilio sees FY 2017 EPS of ($0.23)-($0.22). Twilio sees FY 2017 revenue of $386.5-388.5 million.

Medtronic plc (NYSE: MDT) 2.2% HIGHER; announced its preliminary revenue for its second quarter of fiscal year 2018, which ended October 27, 2017. The company announced preliminary second quarter worldwide revenue of approximately $7.050 billion. (Street sees Q2 revenue of $6.87 billion).

Ringcentral, Inc. (NYSE: RNG) 2% HIGHER; reported Q3 EPS of $0.06, $0.02 better than the analyst estimate of $0.04. Revenue for the quarter came in at $129.8 million versus the consensus estimate of $125.9 million.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Special Reports

Related Entities

Soros Fund Management, Stock Buyback, Pre-Open Losers, Pre-Open Winners, Pre Market Movers, FDA